At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
Crenolanib besylate +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
In Brief
A Phase 2 clinical trial evaluating Crenolanib besylate, Idarubicin, and 6 other interventions for Acute Myeloid Leukemia. Completed, enrolled 28 participants across 1 site.
Detailed Summary
This is an open label, two-arm, Phase I-II trial, non-randomized. Arm 1: crenolanib with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin) Arm 2: crenolanib with 5-azacitidine
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartSep 2015
Primary CompletionJul 2020
TodayJul 2026
First PostedMar 27, 2015
Enrollment StartSep 1, 2015
Primary CompletionJul 15, 2020
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 11.3 years ago
Interventions
Crenolanib besylatedrug
Idarubicindrug
Cytarabinedrug
Azacytidinedrug
Mitoxantronedrug
Etoposidedrug
Fludarabinedrug
G-CSFdrug